ライフサイエンスコーパス: activity against

1 HA VLP vaccines elicited antibodies with HAI activity against 11 to 14 of the 15 H1N1 viruses isolate

2 ated highly efficient antioxidant scavenging activity against 2,2-diphenyl-1-picrylhydrazyl free radi

3 romolar or submicromolar in vitro cytostatic activities against a broad panel of cancer and leukemia

4 thermore, these immune sera showed antiviral activities against a panel of genetically distinct HCMV

5 t CDK2 and CDK9 and potent antiproliferative activities against a panel of tested tumor cell lines al

6 Ps) are innate immune molecules that exhibit activities against a range of microbes, including bacter

7 SGN-CD19B demonstrated activity against a broad panel of malignant B-cell lines

8 pounds with balanced, highly potent in vitro activity against a broad range of bacterial isolates wer

9 H2S is associated with significant antiviral activity against a broad range of emerging enveloped RNA

10 nfolding and exhibited reduced glycosylation activity against a complex array of glycosylation substr

11 -positive organisms, into an antibiotic with activity against a diverse panel of multi-drug-resistant

12 notype (GT) 1a, grazoprevir maintains potent activity against a majority of NS3 resistance-associated

13 es that display little or no differential in activity against a matched pair of vinblastine sensitive

14 The resultant lead compounds possess potent activity against a multidrug resistant strain of P. falc

15 Evaluation of antibacterial activity against a panel of Gram-positive and Gram-negat

16 egimens elicited antibodies with broader HAI activity against a panel of H3N2 viruses than wild-type

17 Comparisons of the enzyme inhibitory activity against a panel of HDAC isoforms revealed these

18 y, many that exhibit further improvements in activity against a Pgp overexpressing resistant cancer c

19 An assessment of thioesterase activity against a range of acyl-CoA substrates revealed

20 e with a unique mechanism of action and have activity against a range of bacterial pathogens, includi

21 particular, have defensin-like antimicrobial activity against a variety of bacterial taxa at low micr

22 antibiotic that displays formidable in vitro activity against a variety of Gram-positive bacteria.

23 GDC-0810 has robust in vitro and in vivo activity against a variety of human breast cancer cell l

24 , while being completely devoid of antiviral activity against a wide range of DNA viruses.

25 rase I (TOP1) inhibitor, exhibits anti-tumor activity against a wide range of tumors.

26 that HO-1 can exert a significant antiviral activity against a wide variety of viruses, including HI

27 ressed Cry toxin variants showed significant activity against A. aegypti larvae while another induced

28 eceptor (IL6R) and VEGF resulted in enhanced activity against A431-V tumors.

29 its conformation to optimize the antagonist activity against Abeta.

30 of acyl-CoA substrates revealed the greatest activity against acetyl-CoA, and structure-guided mutage

31 These two analogues when used alone lacked activity against Acinetobacter baumannii and Klebsiella

32 s (CARs) targeting CD19 (CAR-19) have potent activity against acute lymphoblastic leukemia, but fewer

33 The conjugates showed potent biological activities against all tested bacteria including a multi

34 cited antibodies with HAI and neutralization activity against all cocirculating variants from 2004 to

35 VLPs elicited high levels of neutralization activity against all four serotypes simultaneously.

36 elpatasvir and pibrentasvir had uniform high activity against all HCV genotypes tested.

37 3 [Ga(ACtpfc)], demonstrated high cytotoxic activity against all NCI60 cell lines derived from nine

38 ative in mice at a single, low dose and show activity against all parasite life stages in multiple in

39 ificities with potent and broad neutralizing activity against all seven HCV genotypes.

40 of these molecules exhibited broad-spectrum activity against all tested fungal strains, with excelle

41 ing Bregs showed strong in vitro suppressive activity against allogeneic CD4(+) T cells, but were def

42 act of Undaria pinnatifida showed inhibitory activity against alpha-amylase, IC50 0.74+/-0.02mg/ml an

43 t capacity of the extract and its inhibiting activity against alpha-glucosidase, pancreatic lipase an

44 annotinolide A, which shows antiaggregation activity against amyloid-beta (Abeta)1-42 peptide aggreg

45 viously as a new scaffold with antibacterial activity against an array of multidrug-resistant staphyl

46 e activity against Candida albicans and good activity against an export-deficient mutant of Escherich

47 ical region of cNK-lysin, have antimicrobial activity against apicomplexan parasites such as Eimeria

48 ith nanomolar to subnanomolar antiplasmodial activity against asexual blood stages of Plasmodium falc

49 RCB-185, a lipophilic prodrug with nanomolar activity against asexual parasites.

50 We compared the NAb activity against autologous and heterologous viruses bet

51 TLM) analogues that show improved whole cell activity against bacterial strains including methicillin

52 e is associated with an increased antibiotic activity against bacterial strains possessing high level

53 The first demonstration of its activity against bacterial viruses (phages) is also the

54 ata suggest that PD-1 immunotherapy may have activity against BCCs, including in those that have been

55 ingly, a PA analog alpha-PanAm showed potent activity against blood stage parasites in vitro; however

56 malaria endemic areas have shown functional activity against blood-stage parasites as judged by an i

57 flocculosa in the context of its biocontrol activity against Blumeria graminis f.sp. hordei as it pa

58 ive of evolutionary optimization of 3-kinase activities against both substrates.

59 WFW (cyclo(RRRWFW)) has a rapid bactericidal activity against both Gram-positive and Gram-negative ba

60 s to a ~10-50-fold greater growth-inhibitory activity against breast cancer cell lines.

61 Trp-His(2-biphenyl)] displayed high in vitro activity against C. neoformans (IC50 = 0.35 mug/mL, MIC

62 e analogs have been shown to exhibit diverse activities against cancer, inflammation, arthritis, and

63 ural isomer of spiroscytalin showed moderate activity against Candida albicans and good activity agai

64 o-3-phosphocholine exhibited good antifungal activity against Candida albicans with MIC of 15.6mug/mL

65 complexes are phototoxic and display potent activity against chemotherapeutically resistant cells.

66 2-b]pyrrole 1b that displayed good antiviral activity against CHIKV infection in vitro.

67 Ponatinib has shown potent activity against chronic myeloid leukaemia that is resis

68 ying conditions along with the anti-swarming activity against Citrobacter rodentium.

69 against class IIa HDACs, but weak inhibitory activity against class I HDACs.

70 vealed these compounds had strong inhibitory activity against class IIa HDACs, but weak inhibitory ac

71 The compounds showed increased activity against clinical isolates of P. aeruginosa, fur

72 otic of the tetracycline class with in vitro activity against clinically important gram-negative, gra

73 Remarkably, D-RR4 demonstrated potent activity against colistin-resistant strains of P. aerugi

74 Our data demonstrate that antimicrobial activities against common pathogens in chronic wounds su

75 -Ar)-Trp-His(2-Ar) exhibit potent antifungal activity against Cryptococcus neoformans with high selec

76 It has shown potent activity against Cryptococcus neoformans, a yeast that c

77 ntitumor ether lipids (GAELs) display potent activity against CSCs.

78 However, their antiviral activities against currently circulating influenza A vir

79 erferon-dependent manner, displays antiviral activity against DENV, and localizes to the DENV replica

80 an interferon-stimulated gene with antiviral activity against DENV, as well as to propose a mechanism

81 f all vaccinated monkeys showed neutralizing activity against DENV2.

82 ctural features responsible for the in vitro activity against different strains of P. falciparum, the

83 in-4(3H)-one based inhibitors show a similar activity against digestive Plms I, II, and IV and >10-fo

84 d be identified and an antifungal agent with activity against diverse fungal pathogens.

85 uggest that glycoside hydrolases can exhibit activity against diverse microorganisms and may be usefu

86 e was generated with differential inhibitory activities against DprE1 and CYP2C9, which provides insi

87 , while a number of them revealed impressive activities against drug resistant human cancer cells, ma

88 polymerase (RNAP) and exhibits antibacterial activity against drug-resistant bacterial pathogens: pse

89 rance, whereas overexpression potentiates AG activity against drug-resistant Mtb.

90 s13 with highly potent in vitro bactericidal activity against drug-susceptible and drug-resistant cli

91 Activity against E. coli was found only when the pools w

92 e bacteria; however zerumbone showed highest activity against E. coli, whereas its derivatives were l

93 lent vaccines elicited strong neutralization activity against each DENV serotype in mice.

94 ies for their antiviral potential, including activity against Ebola virus and bat influenza A-like vi

95 specificity for reduced glutathione, with no activity against either gamma-glutamyl amino acids or ox

96 bits purified ppGalNAc-T3 with no detectable activity against either ppGalNAc-T2 or ppGalNAc-T6.

97 oteins, resulting in intrinsic antibacterial activity against Enterobacteriaceae and restoration of b

98 brane interfaces might exert broad antiviral activity against enveloped viruses.

99 ere with protein-DNA interactions may retain activity against enzalutamide-resistant prostate cancers

100 bB kinase inhibitor erlotinib with nanomolar activity against ErbB4 significantly suppressed diabetic

101 structures that allowed us to control their activity against Escherichia coli in both directions wit

102 ere sufficient to activate SCN antibacterial activity against Escherichia coli In the presence of mul

103 d 1 also showed broad spectrum antibacterial activity against Escherichia coli, Mycobacterium smegmat

104 clic peptide JB-95 with potent antimicrobial activity against Escherichia coli.

105 ia is reported for selected compounds, as is activity against ESKAPE pathogens and recombinant bacter

106 anti-CD25 antibodies have displayed limited activity against established tumors.

107 High activity against extended-spectrum beta-lactamase, methi

108 ts, including those with potent neutralizing activity against fibroblast entry, while all antibodies

109 It exhibits broad-spectrum antifungal activity against filamentous fungi at submicromolar conc

110 Phenolic compounds, their inhibitory activity against fungal amylase and the occurrence of af

111 grafts revealed that 6OTD exhibits antitumor activity against glioblastoma.

112 We show that LPPO II display excellent activities against Gram-positive and -negative bacteria,

113 d topoisomerase IV, displaying antibacterial activities against Gram-positive and Gram-negative patho

114 olysaccharides like guar gum may broaden its activity against gram negatives.

115 ng bis-catechol conjugate, 42, has excellent activity against Gram-negative bacteria including carbap

116 m-positive pathogens, novobiocin has limited activity against Gram-negative organisms due to the pres

117 d-spectrum antibacterial activity, including activity against Gram-negative pathogens.

118 Bacaucin shows broad antibacterial activity against Gram-positive bacteria, but is also hem

119 gyrase and topoisomerase IV) display potent activity against Gram-positive pathogens and no target-m

120 tibiotic thiostrepton, which exhibits potent activity against Gram-positive pathogens.

121 viruses, and 7 viruses induced neutralizing activity against >/=15 of the 20 viruses.

122 with potential prophylactic and therapeutic activities against gut infections.

123 Use of antiretrovirals dually activity against HBV increased over time.

124 derivatives, showed low nanomolar inhibitory activity against hCA II and hCA VII, isoforms involved i

125 und that IFN-alpha and IFN-lambda1 antiviral activity against HCV was impaired in IL28B T/T infected

126 r and leukemia cell lines and some antiviral activity against HCV.

127 nsmitted HD infections and has good in vitro activity against HD strains from both genital and skin u

128 ompounds were evaluated for their anticancer activity against HeLa (cervical cancer), MCF-7 (breast c

129 o R. sempervirens extracts exerted cytotoxic activity against HeLa and HT-29 cell lines, but were ina

130 l clinical trials Triapine showed anticancer activity against hematological diseases, however, studie

131 ac-cryptopleurine, exhibit potent inhibitory activity against hepatitis C virus (HCV) replication in

132 IFN-alpha (peg-IFN-alpha)-induced antiviral activity against hepatitis C virus (HCV) replication.

133 These compounds showed antiviral activity against hepatitis C virus.

134 oxicity, and in vitro nanomolar irreversible activity against herpes simplex virus (HSV), human papil

135 (TDF) disoproxyl fumarate (TDF) has in vitro activity against herpes simplex virus type 2 (HSV-2) and

136 , immunized rabbits also showed neutralizing activities against heterologous tier 2 HIV-1 isolates.

137 , (IZ14N24N)3 possessed promising inhibitory activity against HIV-1 infection and markedly increased

138 olic stability and 39 times higher antitumor activity against hormone-resistant prostate cancer cells

139 gen response element half-site has antitumor activity against hormone-sensitive prostate cancer.

140 unds were tested for their antiproliferative activity against HT-29 colon cancer cell lines.

141 oid which displays potent anti-proliferative activities against human cancer cell lines by inhibiting

142 with CR6261 and CR9114 showed weak in vitro activity against human H2 influenza viruses, but the in

143 ene-6-carboxylate of polyketide origin, with activity against human opportunistic food pathogenic mic

144 ation of antibodies with HA inhibition (HAI) activity against human seasonal H3N2 viruses that were i

145 The total phenolics, scavenging activity against hydroxyl and peroxyl radicals, the redu

146 istance by optimizing inhibitors that retain activity against induced resistant mutants.

147 displaying potent and selective bactericidal activity against key Gram-positive pathogens (including

148 -phosphocholine exhibited good antibacterial activity against Klebsiella planticola with MIC of 15.6m

149 only compound showed obvious antileishmanial activity against Leishmania donovani with an IC50 value

150 and stilbenoids showed potent antibacterial activity against Listeria monocytogenes and methicillin-

151 Pools showed high antibacterial activity against Listeria monocytogenes: cIsf pool had a

152 DSM265 shows in vitro activity against liver and blood stages of P falciparum.

153 FBXW2 has tumour suppressor activity against lung cancer cells and blocks oncogenic

154 in (Cry51Aa2) was reported with insecticidal activity against Lygus spp.

155 and 12 demonstrated excellent antibacterial activity against M. tuberculosis (MIC = 3.13 muM).

156 iNOS is thought to have direct bactericidal activity against M. tuberculosis, the role of NO as a si

157 namide (APYS1) that has potent, bactericidal activity against M. tuberculosis.

158 (Fe/S) cluster is critical for its antiviral activity against many different viruses.

159 tc (LtnA1 and LtnA2) that displays nanomolar activity against many Gram-positive bacteria.

160 nds, 9f showed substantial antiproliferative activity against MCF-7 and HL-60 cells with IC50 of 6.13

161 assay, where they showed highest inhibitory activity against MCF-7.

162 nt Amyris texana was found to have selective activity against MDA-MB-453 cells, a model of the lumina

163 luate new antibiotics with improved in vitro activity against MDR pathogens using recently updated gu

164 Although the hybrid possesses potent activity against MDR, P. aeruginosa isolates the activit

165 All wine microcapsules revealed significant activity against medically important bacterial strains.

166 drug, P-SMART showed significant anticancer activity against melanoma cells in cytotoxicity, colony

167 hycoic acid A (1) showed moderate antibiotic activity against methicillin-resistant Staphylococcus au

168 acid backbones and exhibit potent antibiotic activity against methicillin-resistant Staphylococcus au

169 Antibacterial activity against model Gram negative and Gram positive b

170 demonstrate that they possess low nanomolar activity against models of acute myeloid leukemia (AML)

171 odies with hemagglutination inhibition (HAI) activity against more H1N1 viruses in the panel than VLP

172 Fosfomycin maintains activity against most Escherichia coli clinical isolates

173 -penetrant ALK and ROS1 TKI with preclinical activity against most known resistance mutations, in pat

174 analogues, demonstrate potent antibacterial activities against MRSA, MRSE and VRE (MIC = 0.003-0.78

175 ipid peroxidation inhibition), antibacterial activity against MRSA and MSSA and cytotoxicity against

176 layed a promising extracellular bactericidal activity against MRSA at concentrations equal to and fou

177 d heptapeptide, shows specific antibacterial activity against MRSA by a membrane-disruptive mechanism

178 , both peptides exhibited good antibacterial activity against MRSA, vancomycin-resistant S. aureus, l

179 Isavuconazole showed activity against mucormycosis with efficacy similar to a

180 elope vulnerability may display differential activity against mucosal infection.

181 products, which exhibit potent antimicrobial activities against multidrug-resistant pathogens.

182 sized, and evaluated for their antibacterial activity against multidrug resistant (MDR) Gram-positive

183 ncomplicated falciparum malaria due to their activity against multidrug resistant parasites.

184 t effective antimicrobial peptides displayed activity against multidrug-resistant clinical isolates o

185 -16 exhibits antiproliferative and cytotoxic activities against multiple cancer cell lines, with IC(5

186 kinase activity that demonstrates equipotent activity against multiple MyD88-dependent responses both

187 E209 has potent nanomolar inhibitory activity against multiple strains of P. falciparum and P

188 splay reduced binding to and lower enzymatic activity against multivalent substrates, resulting from

189 ds, their time-kill studies, their hemolytic activity against murine erythrocytes, as well as their c

190 vation and showed restored antimycobacterial activity against Mycobacterium avium and Mycobacterium b

191 hemically unstable antibiotic with selective activity against Mycobacterium tuberculosis (Mtb) due to

192 in, a novel macrolide antibiotic with potent activity against Mycobacterium tuberculosis H37Rv.

193 emia and other lymphoid cancers, it also has activity against myeloid neoplasms, such as Erdheim-Ches

194 tion with Bexsero elicits serum bactericidal activity against N. cinerea, which is primarily directed

195 weak cytotoxicity and significant inhibitory activity against nitric oxide (NO) production.

196 inst S. aureus and in cellulo antiretroviral activity against NNRTI-resistant strains.

197 talytic p38 inhibitors may derive from their activity against noninflammatory p38 isoforms (e.g., p38

198 ed in clinical trials because of their broad activity against numerous MMP family members and the ser

199 ction and displayed broad-spectrum antiviral activity against other alphaviruses and CHIKV isolates b

200 pecific clones exhibited robust bactericidal activity against P. acnes, and complete breaches in the

201 DJK-5 showed stronger inhibitory activity against P. aeruginosa associated with plastic c

202 However, anti-Psl mAb activity against P. aeruginosa biofilms is unknown.

203 c shows in vivo prophylactic and therapeutic activity against P. aeruginosa during gut infection in t

204 eted by hCVAM and directly contribute to its activity against P. aeruginosa.

205 azol-3(2H)-ones display nanomolar inhibitory activity against P. falciparum and P. vivax IspD and pre

206 d compounds that possess potent antimalarial activity against P. falciparum parasites comparable to t

207 y towards the pre-erythrocytic stage (98% of activity against P. gallinaceum), thus suggesting that i

208 in the P. berghei mouse model and additional activity against parasite liver and gametocyte stages, m

209 al drugs that have remarkable broad spectrum activity against parasites, mycobacteria, and anaerobic

210 ized NSC319726 and its reasonable inhibitory activity against pathogens suggest advancing this compou

211 pact on ligand binding and antiproliferative activity against PDAC cells.

212 The explanation for this wide difference in activity against peptides or other linear substrates com

213 ert selective nanomolar or even subnanomolar activity against PI4KB as well as profound antiviral eff

214 a more rapid short term rate of elution and activity against planktonic and lawn biofilms.

215 biofilm exopolysaccharide exhibit protective activity against planktonic bacteria in acute infection

216 and synthetic diastereomers 5a and 5c showed activity against Plasmodium falciparum malaria parasites

217 Compounds 11-13 showed strong antiplasmodial activity against Plasmodium falciparum with IC50 values

218 n proteins showed polyester depolymerization activity against polylactic acid and polycaprolactone.

219 characterized by screening their biochemical activities against potential MIA substrates harvested fr

220 sone or vincristine demonstrated synergistic activity against pre-BCR(+) ALL.

221 haride (SSPS) nanoparticles and evaluate the activities against proliferation of human colon HCT116 a

222 as evaluated by DPPH assay and antibacterial activity against Pseudomonas aeruginosa and Staphylococc

223 compound demonstrated the best antibacterial activity against Pseudomonas aeruginosa both in vitro an

224 trum molecule with a unique species-specific activity against Pseudomonas aeruginosa.

225 mpanzee sera also showed robust neutralizing activity against RABV and pseudo-typed EBOV.

226 s were further screened for their inhibitory activity against recombinant HDAC1-3, HDAC6, and HDAC8.

227 We report that while KDU691 shows no activity against rings, it is highly inhibitory against

228 ize rMuVJL5 infection had cross-neutralizing activity against rMuVJL5-F/HNBMV.

229 sociated with lower T1D risk exhibit reduced activity against rotavirus infection.

230 oach was utilized to identify fragments with activity against Rpn11.

231 ull agonist or positive allosteric modulator activity against RXFP1.

232 are characterized by a potent antibacterial activity against S. aureus and in cellulo antiretroviral

233 for antagonizing or potentiating antibiotic activity against S. aureus.

234 Carolacton has remarkably specific activity against S. mutans, causing acid-mediated cell d

235 uiting chemokines all displayed bactericidal activity against S. pneumoniae, but only CCL26 and CCL28

236 yed with as low as 10 nM enzyme to determine activity against S/T/Y-containing peptides; additionally

237 e show that adenosine harbors bacteriostatic activity against Salmonella enterica serovar Typhimurium

238 nds representing new chemical scaffolds have activity against schistosomula and adult worms at low mi

239 tolytic and exhibits lysozyme-mediated lytic activity against several bacterial species.

240 4/6 inhibitors have shown promising clinical activity against several cancer types, including melanom

241 in, the hydrolysates demonstrated inhibitory activity against several gram-positive and gram-negative

242 perone that has demonstrated neuroprotective activity against several intracellular amyloids.

243 In vitro tests revealed peptides with high activity against several lymphoma types and low cytotoxi

244 isplayed low mammalian cytotoxicity and good activity against several M. tuberculosis clinical isolat

245 e of celecoxib that demonstrated preclinical activity against several microbial diseases.

246 inhibitors of CDK4/6 have shown significant activity against several solid tumours.

247 safety therapy profile with broad antitumor activity against solid and hematological malignancies in

248 atch interactions or the entire lid enhanced activity against soluble ester substrates, and hydrogen-

249 immune response and to exhibit pro-apoptotic activity against some tumor cells.

250 ts exhibited calcium-dependent antimicrobial activity against Staphylococcus aureus and Bacillus subt

251 transcription factor STAT5 confer inhibitory activity against STAT3.

252 GSK3532795 demonstrated potent antiviral activity against subtype B (monotherapy or with ATV +/-

253 for each agent that will maximize antiviral activity against susceptible and drug-resistant subpopul

254 also found to possess comparable inhibitory activity against T cells, indicating a potentially conse

255 and invasion and shows strong antiparasitic activity against T. gondii The same compound inhibits in

256 se compounds all displayed strong inhibitory activity against T.b. brucei but none of them had higher

257 op metabolically stable inhibitors with high activities against the osimertinib resistant L858R/T790M

258 ified compound showed significant antifungal activities against the potential saprobic competitors.

259 tive EGFR inhibitor (2) as a starting point, activities against the single mutants (L858R and del746-

260 ion of 4000 mg/L showed a higher antioxidant activity against the ABTS radical (3.21 muMol/g) in comp

261 Moreover, 1o has a remarkable activity against the blood-feeding trematode parasite Sc

262 ligands with different modes of antagonistic activity against the CXCR4-CXCL12 axis have been develop

263 Compound 1 and DBL displayed activity against the cyanobacteria Microcystis aeruginos

264 xcellent parasite selectivity, and nanomolar activity against the earliest forms of gametocyte develo

265 afe drug treatment with substantial curative activity against the filarial nematodes responsible for

266 (1) is an unusual diterpene with remarkable activity against the H1N1 influenza virus.

267 CR9114 did not display in vitro neutralizing activity against the human H2 virus.

268 the yeast Pichia pastoris was found to have activity against the important plant pathogen Sclerotini

269 is a chiral compound which exerts antiviral activity against the influenza A virus by inhibiting pro

270 hibitors of the PASTA kinases that have both activity against the intact microbe and high kinase spec

271 kout hosts revealed increased autoaggression activity against the liver.

272 Compound 13 showed moderate activity against the MDR Gram-negative strains, with MIC

273 oid alkaloids that exhibit potent inhibitory activity against the opportunistic fungal pathogens Cand

274 34, demonstrated excellent growth inhibitory activity against the parasite, with potency equal to tha

275 in is a small-molecule kinase inhibitor with activity against the receptor tyrosine kinase FLT3, and

276 and the reduction in differential functional activity against the sensitive and Pgp overexpressing re

277 rophotometric rate determination for trypsin activity against the substrate N-benzoyl-DL-arginine p-n

278 e HP-beta-CD samples showed generally higher activity against the test microorganisms compared to IN

279 ropanol) showed dose-dependent antimicrobial activity against the tested pathogenic bacteria and fung

280 signaling and has potent anti-proliferative activity against therapy-sensitive and therapy-resistant

281 were not able to elicit antibodies with HAI activity against these cocirculating strains.

282 was well tolerated and demonstrated clinical activity against these endemic fungi with a safety profi

283 two oxazole natural products with selective activity against this cell line.

284 ss of antimalarials, especially due to their activities against three stages of the parasite's life c

285 e superinfected had significantly weaker NAb activity against tier 1 subtype B viruses (P = 0.003 for

286 ted-7H-pyrrolo[2,3-d]pyrimidines with potent activity against TNBC tumor cell lines.

287 pM), coupled with a single-digit micromolar activity against Trypanosoma brucei brucei (EC50 = 2.97

288 This superior activity against tuberculosis could be adoptively transf

289 matory properties and cell growth inhibitory activity against tumor cells.

290 nerate long-term immune memory and decreased activities against tumour-cell subpopulations with low t

291 valent to Tyrc A against S. aureus, enhanced activity against two Gram negative strains and maintaine

292 vided analogs with more potent and selective activity against two LAR subtype cell line models, culmi

293 inhibitors also possess moderate inhibitory activities against tyrosyl-DNA phosphodiesterase 1 (TDP1

294 Anticancer activity against various malignancies was typically test

295 It had potent anti-proliferative activity against various melanoma cell lines and could i

296 luenza therapeutics with a broad spectrum of activity against various subtypes is necessary to mitiga

297 e solubility and safety without compromising activity against VL.

298 These compounds possess potent activity against VRE, inhibiting growth of clinical isol

299 I), low cytotoxicity, and enhanced antiviral activity against wild-type (WT) HIV-1 RT and resistant v

300 of favipiravir, a polymerase inhibitor with activity against ZIKV, we predict a dose of 150 mg/kg gi